Drug intelligence / Profile preview

Kylo-03

Development stage: Preclinical
Lead developer: Kylonova Biopharma
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Subcutaneous

Overview

Kylo-03 is an investigational small interfering RNA (siRNA) therapeutic developed by Kylonova for the treatment of hypertriglyceridemia and related dyslipidemias. The drug utilizes Kylonova's proprietary Nano-lipid Particles Delivery Platform (NPDP) to deliver siRNA specifically to hepatocytes in the liver. Once inside the cells, Kylo-03 targets and degrades the mRNA encoding Angiopoietin-like 3 (ANGPTL3), a key regulator of lipid metabolism that inhibits lipoprotein lipase (LPL) and endothelial lipase (EL). By silencing the expression of ANGPTL3, Kylo-03 aims to enhance the clearance of triglycerides and lower serum levels of LDL cholesterol and other lipids. It is currently in the pre-clinical or IND-enabling stage of development.

Targets

ANGPTL3 (Angiopoietin-like protein 3)

Beyond the preview

Go deeper on Kylo-03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kylo-03.

Explore the full profile